Skip to main content
Contact Us
Subscribe
E-Edition
82°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biondvax Pharma ADR
(NQ:
BVXV
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Sep 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biondvax Pharma ADR
< Previous
1
2
3
4
5
Next >
BiondVax Presenting at BIO CEO & Investor Conference
February 02, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
Research Links Two Natural Deposits to Onset of Macular Degeneration
January 31, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study
January 30, 2023
Via
Investor Brand Network
Exposures
COVID-19
Toddlers, Infants Risk Severe Outcomes When Faced with Multiple Infections
January 24, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19
January 23, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
January 23, 2023
Via
Investor Brand Network
Exposures
COVID-19
Product Safety
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
January 23, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
Scientists Discover Unknown T Cell Function That Can Help Fight Fungal Infections
January 17, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs
January 17, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs
January 13, 2023
Via
Investor Brand Network
Exposures
COVID-19
America Faces Shortage of Infectious Disease Experts
January 09, 2023
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus
January 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform
January 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
January 06, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Announces Participation in Upcoming Biotech Showcase
January 05, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax to Present at Biotech Showcase 2023
January 05, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements
January 04, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Letter to Shareholders
January 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax CEO Issues Letter to Shareholders
December 30, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market
December 29, 2022
Via
Investor Brand Network
Exposures
COVID-19
New Research Shows Brain Stimulation Improves Reading Ability of Macular Degeneration Patients
December 28, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Aegis Capital Corp. Acted as Sole Bookrunner on BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) $8M Underwritten Public Offering
December 22, 2022
Via
Investor Brand Network
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)
December 21, 2022
Via
ACCESSWIRE
Experts Push for More Studies into Link Between Asthma, Female Sex Hormones
December 21, 2022
Via
Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Closes $8M Underwritten Public Offering
December 20, 2022
Via
Investor Brand Network
BiondVax Announces Closing of $8 Million Underwritten Public Offering
December 20, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raid $8M
December 16, 2022
Via
Investor Brand Network
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
December 16, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast
December 13, 2022
Via
Investor Brand Network
Exposures
COVID-19
Psoriasis Patients Report Being Embarrassed Because of Flare-Ups in Intertriginous Areas
December 13, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.